Pharmaceutical Lipid-Based Excipients Global Market Report 2025

The pharmaceutical lipid-based excipients market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.79 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to several factors, including the increasing prevalence of poorly water-soluble drugs, higher demand for controlled and targeted drug release, a rise in pharmaceutical investments, the expansion of oral solid dosage forms, a greater focus on improving drug bioavailability, and the regulatory acceptance of lipid excipients in innovative formulations.

The pharmaceutical lipid-based excipients market size is expected to see strong growth in the next few years. It will grow to $2.22 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be attributed to the increasing demand for advanced drug delivery systems, the growing adoption of mRNA and gene therapies, an expanding pipeline of poorly water-soluble drugs, a stronger focus on personalized medicine, supportive regulatory frameworks, and strategic investments in biopharmaceutical manufacturing infrastructure. Key trends during this period include innovations in lipid nanoparticle delivery systems, wider adoption of mRNA and gene therapies, enhanced solubility solutions for poorly water-soluble drugs, the expansion of biocompatible and sustainable lipid sources, improved manufacturing scalability, and greater use in oral and injectable formulations.

The growth of gene therapy is expected to accelerate the expansion of the pharmaceutical lipid-based excipients market. Gene therapy involves modifying or manipulating a person’s genes to treat or prevent disease. Its rise is largely driven by advancements in delivery systems that ensure safe, efficient, and targeted transport of genetic material into cells. Pharmaceutical lipid-based excipients play a crucial role in enhancing gene therapy by enabling efficient delivery systems, providing stability, and ensuring the targeted transport of genetic material. These excipients improve therapeutic outcomes by protecting nucleic acids and facilitating cellular uptake, thereby increasing the effectiveness of modern treatments. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based non-profit organization, reported that the U.S. Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five in 2022. This growing trend in gene therapy is driving the demand for pharmaceutical lipid-based excipients.

Leading companies in the pharmaceutical lipid-based excipients market are making strategic investments to foster innovation, enhance formulation capabilities, and support drug delivery research. A notable example is Gattefossé SAS, a France-based chemical manufacturing company, which opened a state-of-the-art Technical Center of Excellence in Mumbai in November 2024. This facility aims to support India’s growing pharmaceutical market, offering specialized laboratories and tailored support for excipient innovation, particularly in bioavailability, sustained release, and topical formulations. It will also strengthen Gattefossé’s position in the Asia-Pacific region. The new facility is designed to encourage collaboration and foster innovation, providing a productive environment for research in pharmaceutical and personal care applications.

In June 2024, CordenPharma, a pharmaceutical company based in Switzerland, formed a partnership with Certest Biotec S.L., a Spain-based biotechnology company. The collaboration aims to integrate Certest’s proprietary ionizable lipids into CordenPharma’s lipid nanoparticle (LNP) formulation services. This partnership is set to enhance the development of RNA/DNA-based therapeutics by combining the expertise of both companies in lipid innovation, manufacturing, and regulatory compliance. Certest Biotec specializes in drug delivery through lipid nanoparticles (LNPs) and the synthesis of active pharmaceutical ingredients (APIs).

Major players in the pharmaceutical lipid-based excipients market are Cargill Incorporated, BASF SE, Merck KGaA, FUJIFILM Corporation, Evonik Industries AG, DuPont de Nemours Inc., Stepan Company, Croda International, Ashland Corporation, NOF CORPORATION, CordenPharma, SEPPIC, Nippon Fine Chemical Co. Ltd., Cayman Chemical, ABITEC Corporation, Creative Biolabs, IOI Oleo GmbH, Lipoid, RuixiBiotechCo.Ltd, Biosynth.

Europe was the largest region in the pharmaceutical lipid-based excipients market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceutical lipid-based excipients report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharmaceutical lipid-based excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pharmaceutical lipid-based excipients are inactive substances derived from lipids that are used in drug formulations to aid in the delivery, stabilization, or enhancement of the absorption of the active pharmaceutical ingredient (API). These excipients are designed to improve the solubility, stability, and bioavailability of drugs, especially those that are poorly soluble in water.

The main types of pharmaceutical lipid-based excipients include oils, hydrogenated vegetable oils, glyceryl mono caprylate/caprate (GMCC), hard fats, medium-chain triglycerides, lecithin and phospholipids, sodium oleate, caprylic mono- and diglycerides, and others. Oils serve as non-aqueous carriers, enhancing the solubility of lipophilic drugs and improving their oral bioavailability. These excipients are used in various formulations such as oral, parenteral, topical, ophthalmic applications, suppositories, and more. They are employed in the treatment of a broad range of conditions, including cardiovascular diseases, neurological disorders, cancer, metabolic disorders, hormonal imbalances, and infectious diseases. Lipid-based excipients are formulated for all age groups pediatric (0-18 years), adult (19-64 years), and geriatric (65+ years). The key end users include pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and others.

The pharmaceutical lipid-based excipients treatment market research report is one of a series of new reports that provides pharmaceutical lipid-based excipients treatment market statistics, including the pharmaceutical lipid-based excipients treatment industry global market size, regional shares, competitors with the pharmaceutical lipid-based excipients treatment market share, detailed pharmaceutical lipid-based excipients treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical lipid-based excipients treatment industry. This pharmaceutical lipid-based excipients treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical lipid-based excipients market consists of sales of lipid excipients, specialty formulations, sterols, waxes, and glycolipids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.